Submitted by la334 on Tue, 29/09/2026 - 11:57
Researchers in the University of Cambridge’s Department of Psychiatry are developing a UK clinical trial of MDMA-assisted group therapy for people living with post-traumatic stress disorder (PTSD).
The work, led by Dr Liliana Galindo of the Cambridge Psychedelic Research Group in partnership with the charity Supporting Wounded Veterans, was recently featured in The Telegraph.
The proposed study aims to include veterans, first responders and war correspondents, particularly people whose PTSD has not responded adequately to established treatments. It will investigate whether combining pharmaceutical-grade MDMA with preparation, supervised therapy and follow-up sessions in a group setting could offer another approach to trauma treatment.
MDMA-assisted therapy remains an investigational treatment in the UK. International trials have reported greater reductions in PTSD symptoms among participants receiving MDMA-assisted therapy than among those receiving the same therapeutic programme with a placebo. Further research is needed to understand its benefits, risks and suitability for different groups.
The Cambridge study is in development and subject to the necessary regulatory approvals. It is intended to build evidence about whether group therapy could provide a safe, effective and more accessible approach for people living with severe PTSD.
Find out more about the Cambridge Psychedelic Research Group and Project Renew.